Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit-Reference-Cited by-同舟云学术

Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit

Published:2023-05-26 Issue:7 Volume:40 Page:2965-2984
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Al Saleh Yousef^ORCID,Al Busaidi Noor,Al Dahi Waleed,Almajnoni Munawar^ORCID,Mohammed Al Saeed^ORCID,Alshali Khalid^ORCID,Al-Shamiri Mostafa^ORCID,Al Sifri Saud,Arafah Mohammed^ORCID,Chan Siew Pheng^ORCID,El-Tamimi Hassan,Hafidh Khadija^ORCID,Hassanein Mohamed^ORCID,Shaaban Ashraf,Sultan Ali^ORCID,Grassi Guido

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02529-7.pdf

Reference81 articles.

1. World Health Organization. Cardiovascular diseases (CVDs). 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed Oct 24, 2022.

2. International Diabetes Federation. IDF diabetes atlas, 10th edition. 2021. Brussels, Belgium. https://www.diabetesatlas.org. Accessed Oct 18, 2022.

3. Meo SA, Usmani AM, Qalbani E. Prevalence of type 2 diabetes in the Arab world: impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci. 2017;21:1303–12.

4. NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–80.

5. Abboud M, Karam S. Hypertension in the Middle East: current state, human factors, and barriers to control. J Hum Hypertens. 2022;36:428–36.